Bli medlem
Bli medlem

Du är här

2017-03-27

Oncopeptides AB: Oncopeptides AB issues 977,906 shares additionally in connection with offer to acquire shares and listing on Nasdaq Stockholm (the "Offering")

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA,
SOUTH AFRICA OR JAPAN.

On 26 March 2017, the board of directors of Oncopeptides, pursuant to
the request by the Joint Global Coordinators (defined below),
resolved to issue 977,906 shares to ABG Sundal Collier AB.
Oncopeptides will thereby be provided with additional funds of
approximately SEK 45 million, which means that the Company will have
been provided with a total of approximately SEK 695 million through
the Offering, before deduction of issue expenses.

For more information please visit: www.oncopeptides.se

This information is such that Oncopeptides is obliged to disclose
pursuant to the EU Market Abuse Regulation. The information was
released for public disclosure, through the agency of the contact
persons above, on 27 March 2017 at 08.00 a.m. (CET).

-----------------------------------------------------------
http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=417911...
http://mb.cision.com/Main/15404/2223808/648290.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.